Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.32 |
| ▸ | CDC25B | P30305 | 4/20 | 0.32 |
| ▸ | BCHE | P06276 | 2/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12243178 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL20553048 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL20477154 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL27086511 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL29727834 | 1.00 | PDE2A (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| Maleic Acid SCHEMBL20552110 | 0.94 | TMPRSS2 (0.36) | PDE2ATMPRSS2HSPA5PTPN1CDC25B | |
| SCHEMBL24158032 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL22646505 | 0.92 | PDE2A (0.38) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL14817042 | 0.92 | HSPA5 (0.35) | PDE2ATMPRSS2HTR1AHSPA5PTPN1 | |
| SCHEMBL12393267 | 0.91 | PDE2A (0.35) | PDE2AHTR1AHSPA5PTPN1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112279855-B | Method for continuously preparing Rudexilvir intermediate by using microchannel reactor | 南京先进生物材料与过程装备研究院有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-116874491-B | N-protected pyrrolotriazine carbon glycoside compound and preparation method thereof | Shenzhen Antai weishengwu Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| EP-4591935-A2 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2025-07-30 | — | — | EP | disclosed |
| EP-4588928-A2 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | Gilead Sciences, Inc. (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250179012-A1 | SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-113549120-B | Method for preparing ribonucleoside | 吉利德科学公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-113493480-B | Preparation and analysis method of Ruidexivir isomer | 南京正大天晴制药有限公司 | 2025-04-15 | — | — | CN | disclosed |
| EP-4036099-B1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240409575-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | GILEAD SCIENCES, INC. | 2024-12-12 | — | — | US | disclosed |
| CN-118994170-A | Process for preparing 1' -cyanonucleosides | 吉利德科学公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-3212174-B1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| EP-3212175-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | Gilead Sciences, Inc. (US) | 2017-09-06 | — | — | EP | disclosed |
| US-9724360-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| WO-2016069827-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016069825-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. (US) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | GILEAD SCIENCES, INC. | 2016-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409575-A1 | METHODS OF PREPARING 1'-CYANO NUCLEOSIDES | PNP, TYMP, DUT | PDE2A 542/4885TMPRSS2 4740/4885HTR1A 1323/4885 |
| US-20160122356-A1 | METHODS FOR THE PREPARATION OF RIBOSIDES | PRPS1, PRPF4, PRPF31 | PDE2A 2331/4885TMPRSS2 3100/4885HTR1A 4324/4885 |
| US-20160361330-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | PDE2A 1112/4885TMPRSS2 1951/4885HTR1A 4636/4885 |
| US-20250179012-A1 | SYNTHESIS OF SULFUR(VI) COMPOUNDS AND REAGENTS FOR SAME | TST, CBS, SQOR | PDE2A 4682/4885TMPRSS2 4155/4885HTR1A 4458/4885 |
| US-20160122374-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | PDE2A 1112/4885TMPRSS2 1951/4885HTR1A 4636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.